Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-02-06, Stock:JNJ, The news for the past five days is as follows:
2018-01-30: NEWS1: Eli Lilly’s 4Q17 Estimates: Human Pharmaceuticals Business.NEWS2: Better Buy: Intuitive Surgical vs. Johnson & Johnson.NEWS3: Better Buy: Intuitive Surgical vs. Johnson & Johnson.NEWS4: Johnson & Johnson’s Segment-Wise Performance in 4Q17.NEWS5: Better Buy: Intuitive Surgical vs. Johnson & Johnson.NEWS6: Pfizer's new tax rate higher than investors hoped, shares fall.NEWS7: US officials seek packaging fix for diarrhea-drug abuse.NEWS8: Johnson & Johnson’s Growth Rate for 4Q17.NEWS9: Analysts’ Estimates for Eli Lilly’s 4Q17 Earnings.NEWS10: Johnson & Johnson’s Revenues Rose 11.5% in 4Q17.NEWS11: Pfizer (PFE) Stock Falls Despite Q4 Earnings & Sales Beat.NEWS12: Pfizer (PFE) Stock Falls Despite Q4 Earnings & Sales Beat.NEWS13: FDA asks drugmakers to limit amount of opioid drug in packaging.NEWS14: Caution Flag Is Out on Johnson & Johnson's Stock.NEWS15: The Zacks Analyst Blog Highlights: Johnson & Johnson, Illinois Tool Works, Bank of New York Mellon, Ford and Capital One Financial.NEWS16: The Zacks Analyst Blog Highlights: Johnson & Johnson, Illinois Tool Works, Bank of New York Mellon, Ford and Capital One Financial.NEWS17: Diarrhea Drug Imodium Swept Up in Opioid Crisis Under FDA Rules.NEWS18: Pfizer profit tops estimates, books $11 bln tax gain.NEWS19: The Zacks Analyst Blog Highlights: Johnson & Johnson, Illinois Tool Works, Bank of New York Mellon, Ford and Capital One Financial.NEWS20: In Your 70s? 3 Stocks You Might Want to Buy.NEWS21: In Your 70s? 3 Stocks You Might Want to Buy.NEWS22: In Your 70s? 3 Stocks You Might Want to Buy.
2018-01-31: NEWS1: Cramer's lightning round: Take a long-term view on Johnso....NEWS2: Cramer's lightning round: Take a long-term view on Johnson & Johnson.NEWS3: Dow Leads In Tight Finish; Video Gamers Clear Buy Points.NEWS4: Dow Leads In Tight Finish; Video Gamers Clear Buy Points.NEWS5: Stocks Shake Off Post-Fed Slump; Nasdaq Has Best Month in Years.NEWS6: Stocks Shake Off Post-Fed Slump; Nasdaq Has Best Month in Years.NEWS7: Market Close Report: NASDAQ Composite index closes at 7,411.48 up 9 points.NEWS8: Market Close Report: NASDAQ Composite index closes at 7,411.48 up 9 points.NEWS9: Johnson & Johnson to Participate in the Leerink Partners 7th Annual Global Healthcare Conference.NEWS10: Trump needs to pressure drugmakers to let patients use experimental treatments, experts say.NEWS11: Trump needs to pressure drugmakers to let patients use experimental treatments, experts say.NEWS12: Merck’s 4Q17 Estimates: Revenue Growth Expected.NEWS13: Developments in J&J’s Medical Device Business Could Drive Growth.NEWS14: Merck’s 4Q17 Earnings: Analysts’ Estimates.NEWS15: Amgen Gets CHMP Nod to Add ENDEAVOR Data on Kyprolis Label.NEWS16: Amgen Gets CHMP Nod to Add ENDEAVOR Data on Kyprolis Label.NEWS17: Geron Stock Is Heating Up. Time to Buy?.NEWS18: Geron Stock Is Heating Up. Time to Buy?.NEWS19: J&J’s Medical Device Segment Registered Strong Growth in 4Q17.NEWS20: Analysts’ Ratings and Recommendations for Eli Lilly.NEWS21: Johnson & Johnson’s Consumer Business in 4Q17.NEWS22: Amgen Gets CHMP Nod to Add ENDEAVOR Data on Kyprolis Label.NEWS23: Pfizer, Inc. (PFE) Ex-Dividend Date Scheduled for February 01, 2018.NEWS24: Pfizer, Inc. (PFE) Ex-Dividend Date Scheduled for February 01, 2018.NEWS25: Johnson & Johnson’s Medical Devices Business in 4Q17.NEWS26: Geron Stock Is Heating Up. Time to Buy?.NEWS27: Wall Street Is More Optimistic about JNJ Stock after 4Q17 Results.NEWS28: Dolutegravir Franchise to Drive GlaxoSmithKline’s HIV Portfolio.NEWS29: Johnson & Johnson’s Pharmaceuticals Business in 4Q17.NEWS30: The Best Arthritis Drug/Treatment Stocks on the Market Right Now.NEWS31: Drug/Biotech Stocks Q4 Earnings Due on Jan 31: LLY & VRTX.NEWS32: Drug/Biotech Stocks Q4 Earnings Due on Jan 31: LLY & VRTX.
2018-02-01: NEWS1: Johnson & Johnson's Earnings Were Solid, but Questions Remain.NEWS2: Johnson & Johnson's Earnings Were Solid, but Questions Remain.NEWS3: Celgene: How Revlimid Is Positioned after 4Q17.NEWS4: Johnson & Johnson&apos;s Earnings Were Solid, but Questions Remain.NEWS5: Analyzing Celgene’s Performance in 4Q17.NEWS6: Vertex (VRTX) Q4 Earnings Beat on Strong CF Products Sales.NEWS7: Vertex (VRTX) Q4 Earnings Beat on Strong CF Products Sales.NEWS8: Alkermes Submits NDA for Depression Candidate to the FDA.NEWS9: Alkermes Submits NDA for Depression Candidate to the FDA.NEWS10: A Look at Johnson & Johnson’s 2018 Guidance.NEWS11: A Look at Analysts’ Estimates for Johnson & Johnson.NEWS12: 5 Dividend Growth Stocks With Upside To Analyst Targets.NEWS13: 5 Dividend Growth Stocks With Upside To Analyst Targets.NEWS14: Alkermes Submits NDA for Depression Candidate to the FDA.NEWS15: How Tax Reforms Could Affect J&J’s 4Q17 Earnings Results.NEWS16: Johnson & Johnson’s Recent Developments.NEWS17: What Vertex Pharmaceuticals Just Said About Its Future.NEWS18: What Vertex Pharmaceuticals Just Said About Its Future.NEWS19: Market Trends Toward New Normal in Alexander's, Atrion, FS, Gilead Sciences, Abbott Laboratories, and Johnson & Johnson — Emerging Consolidated Expectations, Analyst Ratings.NEWS20: J&J Accelerates Near-Term Goals in Medical Device Business.NEWS21: Johnson & Johnson’s 4Q17 Guidance for Fiscal 2018.NEWS22: What Vertex Pharmaceuticals Just Said About Its Future.
2018-02-02: NEWS1: Roche's New Drugs Aid Growth While Rituxan Continues To Slide In Europe.NEWS2: Roche's New Drugs Aid Growth While Rituxan Continues To Slide In Europe.NEWS3: How Much Can Abbott's Stock Move In 2018?.NEWS4: How Much Can Abbott's Stock Move In 2018?.NEWS5: Biogen: How It Performed in 4Q17.NEWS6: Merck (MRK) Beats on Q4 Earnings, Lags Sales, Guides for '18.NEWS7: Merck (MRK) Beats on Q4 Earnings, Lags Sales, Guides for '18.NEWS8: Noteworthy ETF Inflows: XLV, JNJ, TMO, LLY.NEWS9: Noteworthy ETF Inflows: XLV, JNJ, TMO, LLY.NEWS10: Dow Movers: XOM, JNJ.NEWS11: Dow Movers: XOM, JNJ.NEWS12: Apple, Exxon, Bitcoin Drop; Buffett Likes These Big-Dividend Stocks.NEWS13: Abbott Witnesses Stability in Its International Pediatric Nutrition Sales in 4Q17.NEWS14: Celgene Works toward Cell Therapy for Multiple Myeloma.NEWS15: GlaxoSmithKline Is Focused on Developing Oncology Asset GSK 916.NEWS16: How Tax Reform Affected Abbott’s 4Q17 Performance.NEWS17: Wall Street Analysts’ Recommendations for JNJ in January 2018.NEWS18: These Developments Impacted Abbott Laboratories the Most in Fiscal 2017.NEWS19: How Has Johnson & Johnson Stock Performed Recently?.NEWS20: Johnson & Johnson’s Valuation after Its 4Q17 Earnings.NEWS21: 4 Stocks That Will Profit From Dollar’s Pullback.
2018-02-05: NEWS1: Cramer's sell-off strategy: Have your shopping list ready.NEWS2: Here are some stocks you can buy on the dip: Technician.NEWS3: The Dow just touched correction territory: Here are the stocks that led the drop.NEWS4: Early Prostate Cancer Kept at Bay in Two Studies for High-Risk Men.NEWS5: Notable Monday Option Activity: MS, JNJ, HUN.NEWS6: Notable Monday Option Activity: MS, JNJ, HUN.NEWS7: Health-care ETF tumbles, pressured by pharmaceutical company weakness.NEWS8: Johnson & Johnson falls on report that lawsuits could expose potentially damaging documents.NEWS9: Will Tax Reform Affect Health Care Sector Earnings in 2018?.NEWS10: 3 Top Pharmaceutical Stocks to Buy Now.NEWS11: 3 Top Pharmaceutical Stocks to Buy Now.NEWS12: Bristol Myers earnings power shares in the green among a sea of red.NEWS13: Why Abbott Laboratories’ Product Pipeline Is Expected to Boost 2018.NEWS14: GlaxoSmithKline Is Global Leader in Consumer Healthcare Business.NEWS15: 3 Top Pharmaceutical Stocks to Buy Now.NEWS16: GSK Is Focused on Innovative Assets in Oncology Research Pipeline.NEWS17: Multiple Myeloma May Be Strong Growth Area for GlaxoSmithKline.

Answer: Rise